Is Cognex Stock a Buy or Sell After a Director Dumped Shares Worth $128,000?fool.comThis automation technology leader, known for machine vision systems, reported a notable insider sale amid strong one-year share performance.
Prediction: 3 Stocks That'll Be Worth More Than Walmart 5 Years From Nowfool.comWalmart has crushed the S&P 500 in recent years, but the red-hot stock is due for a cooldown.
Where Will Rocket Lab Stock Be in 10 Years?fool.comThe spaceflight company has shot up like, well, a rocket since its market debut a few years ago.
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decadesfool.comNovartis has a solid portfolio of drugs and a pipeline that should keep the business humming.
JFrog's CTO Sold Shares Worth $2.5 Million. Is the Stock a Buy or Sell?fool.comJFrog, a leader in DevOps software solutions, reported a notable insider sale amid ongoing growth in enterprise adoption.
Is CrowdStrike Stock a Buy After Falling 17% Year to Date?fool.comCrowdStrike is still growing quickly, but the stock's valuation assumes that pace holds up with little noise.
Betting Against Wall Street: The Inverse ETF Surge No One Is Talking Aboutfool.comThe ProShares UltraShort Financials ETF ratchets up bearish bets on a popular sector.
2 Quantum Computing Stocks That Could Make a Millionairequantum-comQuantum computing is still a high-risk frontier, but for patient investors, these two tickers could be tomorrow's generational wealth creators.
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Millionfool.comPraxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Positionfool.comCelcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.
2 Financial Stocks Poised for a Comeback in 2026fool.comBoth stocks are in the Berkshire Hathaway portfolio, selected by former CEO Warren Buffett.
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Convictionfool.comApogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.
My 5 Favorite Dividend Stocks to Buy Right Nowfool.comThere are several solid prospects to choose from right now, but there's a reason I can't get these particular names out of my head.
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emergesfool.comArcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.
